These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34431250)

  • 61. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
    Chen L; Sun J; Yang X
    Cancer Lett; 2016 Jan; 370(1):78-84. PubMed ID: 26472630
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Hepatocellular carcinoma: percutaneous ethanol injection/transarterial chemoembolization/radiofrequency thermoablation].
    Allgaier HP; Rossi S; Deibert P; Zuber I; Hering M; Blum HE
    Praxis (Bern 1994); 2000 Jun; 89(24):1056-60. PubMed ID: 10902462
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of preoperative transarterial chemoembolization on the prognosis for patients with resectable hepatocellular carcinoma: a meta-analysis of randomized trials.
    Wang X; Li J; Peng Y; Dai Y; Xu W
    Hepatogastroenterology; 2011; 58(107-108):869-74. PubMed ID: 21830407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent advances in the treatment of hepatocellular carcinoma.
    Padhya KT; Marrero JA; Singal AG
    Curr Opin Gastroenterol; 2013 May; 29(3):285-92. PubMed ID: 23507917
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review.
    Lau WY; Lai EC; Lau SH
    Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.
    Woeste MR; Geller AE; Martin RCG; Polk HC
    Ann Surg Oncol; 2021 Mar; 28(3):1499-1510. PubMed ID: 33393028
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
    Woo HY; Heo J
    Clin Mol Hepatol; 2015 Jun; 21(2):115-21. PubMed ID: 26157747
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Radiological intervention of hepatocellular carcinoma].
    Chung JW; Choi D
    Korean J Gastroenterol; 2005 Apr; 45(4):258-70. PubMed ID: 15843751
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.
    Delhaye C; Hendlisz A; Vouche M
    Curr Opin Oncol; 2019 Jul; 31(4):339-345. PubMed ID: 30896451
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Management of hepatocellular in the United States.
    Mokdad AA; Hester CA; Singal AG; Yopp AC
    Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination treatment including targeted therapy for advanced hepatocellular carcinoma.
    Lin J; Wu L; Bai X; Xie Y; Wang A; Zhang H; Yang X; Wan X; Lu X; Sang X; Zhao H
    Oncotarget; 2016 Oct; 7(43):71036-71051. PubMed ID: 27626176
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma.
    Darnell A; Belmonte E; Reig M; Brú C
    Radiologia (Engl Ed); 2018; 60(5):424-436. PubMed ID: 30196841
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Advances in Local and Systemic Therapies for Hepatocellular Cancer.
    Mokdad AA; Singal AG; Yopp AC
    Curr Oncol Rep; 2016 Feb; 18(2):9. PubMed ID: 26769114
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma.
    Xu LT; Zhou ZH; Lin JH; Chen Z; Wang K; Wang P; Zhu XY; Shen YH; Meng ZQ; Liu LM
    Eur J Surg Oncol; 2011 Mar; 37(3):245-51. PubMed ID: 21195578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma.
    Li X; Liang P; Ye X
    J Cancer Res Ther; 2020 Sep; 16(5):957-959. PubMed ID: 33004734
    [No Abstract]   [Full Text] [Related]  

  • 80. mRECIST for HCC: Performance and novel refinements.
    Llovet JM; Lencioni R
    J Hepatol; 2020 Feb; 72(2):288-306. PubMed ID: 31954493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.